Alan Skarbnik, MD

Lymphoma and CLL Program, Novant Health Cancer Institute

Poster(s):

• 1424 - Safety Analysis of Fixed-Duration Acalabrutinib-Venetoclax Combinations vs Chemoimmunotherapy: A Post Hoc Analysis From the Phase 3 AMPLIFY Trial

• 1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study